更昔洛韦可渗透进入患有先天性巨细胞病毒感染的婴儿的脑脊液中。
Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection.
作者信息
Natale Fabio, Bizzarri Bianca, Cardi Veronica, Gaeta Aurelia, Villani Paola, Liuzzi Giuseppina, De Curtis Mario
机构信息
Department of Pediatrics and Child Neuropsychiatry, "La Sapienza" University of Rome, Rome, Italy.
Neonatal Intensive Care Unit, Department of Pediatrics and Child Neuropsychiatry, "Sapienza" University of Rome, V.le Regina Elena 324, 00161, Rome, Italy.
出版信息
Ital J Pediatr. 2015 Mar 31;41:26. doi: 10.1186/s13052-015-0132-8.
Abstract
Currently, there is no evidence whether ganciclovir, or its oral prodrug valganciclovir, penetrates into the cerebrospinal fluid of human infants treated for congenital cytomegalovirus infection. Here, we report a case study providing evidence that ganciclovir, administered as valganciclovir, reaches the infant's cerebrospinal fluid when used at the currently recommended dose for congenital cytomegalovirus infection.
摘要
目前，尚无证据表明更昔洛韦或其口服前体药物缬更昔洛韦能否渗透到接受先天性巨细胞病毒感染治疗的人类婴儿的脑脊液中。在此，我们报告一项病例研究，该研究提供了证据表明，以缬更昔洛韦形式给药的更昔洛韦在用于先天性巨细胞病毒感染的当前推荐剂量时可到达婴儿的脑脊液中。
相似文献
1
Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection.
Ital J Pediatr. 2015 Mar 31;41:26. doi: 10.1186/s13052-015-0132-8.
2
Oral valganciclovir treatment for congenital cytomegalovirus infection.
Pediatr Int. 2011 Apr;53(2):249-52. doi: 10.1111/j.1442-200X.2010.03217.x.
3
Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir.
Eur J Pediatr. 2010 Sep;169(9):1061-7. doi: 10.1007/s00431-010-1176-9. Epub 2010 Mar 16.
4
Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants.
Pediatr Infect Dis J. 2007 May;26(5):451-3. doi: 10.1097/01.inf.0000261111.90075.4d.
5
[Prolonged treatment with valganciclovir in an infant with congenital cytomegalovirus infection].
An Pediatr (Barc). 2009 Jun;70(6):578-81. doi: 10.1016/j.anpedi.2009.01.010. Epub 2009 May 7.
6
Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant.
J Perinatol. 2008 Jan;28(1):74-6. doi: 10.1038/sj.jp.7211854.
7
Valganciclovir for treatment of congenital cytomegalovirus infection.
Eur J Pediatr. 2006 Aug;165(8):575-6. doi: 10.1007/s00431-006-0109-0. Epub 2006 Mar 14.
8
Effect on hearing of oral valganciclovir for asymptomatic congenital cytomegalovirus infection.
J Trop Pediatr. 2011 Apr;57(2):132-4. doi: 10.1093/tropej/fmq050. Epub 2010 Jun 24.
9
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
J Infect Dis. 2004 May 1;189(9):1615-8. doi: 10.1086/382753. Epub 2004 Apr 13.
10
Advances in the prevention and treatment of congenital cytomegalovirus infection.
Curr Opin Pediatr. 2016 Feb;28(1):81-5. doi: 10.1097/MOP.0000000000000305.
引用本文的文献
1
[Congenital Cytomegalovirus infection - still a relevant problem (based on own experience and literature)].
Dev Period Med. 2018;22(1):49-57. doi: 10.34763/devperiodmed.20182201.4957.
2
Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature.
Med Microbiol Immunol. 2017 Oct;206(5):347-354. doi: 10.1007/s00430-017-0512-3. Epub 2017 Jul 21.
3
Management of Viral Central Nervous System Infections: A Primer for Clinicians.
J Cent Nerv Syst Dis. 2017 May 1;9:1179573517703342. doi: 10.1177/1179573517703342. eCollection 2017.
本文引用的文献
1
A case of severe ganciclovir-induced encephalopathy.
Case Rep Neurol. 2013 Oct 5;5(3):183-6. doi: 10.1159/000355638. eCollection 2013.
2
Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection.
Curr Drug Metab. 2013 Feb;14(2):208-15.
3
Evidence based management guidelines for the detection and treatment of congenital CMV.
Early Hum Dev. 2011 Nov;87(11):723-8. doi: 10.1016/j.earlhumdev.2011.08.021. Epub 2011 Sep 29.
4
Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.
Clin Microbiol Rev. 2010 Oct;23(4):858-83. doi: 10.1128/CMR.00007-10.
5
Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system.
J Clin Virol. 2009 Dec;46 Suppl 4(Suppl 4):S22-6. doi: 10.1016/j.jcv.2009.08.012. Epub 2009 Sep 18.
6
Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.
J Infect Dis. 2008 Mar 15;197(6):836-45. doi: 10.1086/528376.
7
Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring.
Ann Pharmacother. 2006 Jan;40(1):143-6. doi: 10.1345/aph.1G214. Epub 2005 Dec 20.
8
Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial.
J Pediatr. 2003 Jul;143(1):16-25. doi: 10.1016/s0022-3476(03)00192-6.
9
Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.
Clin Diagn Lab Immunol. 2001 Nov;8(6):1279-81. doi: 10.1128/CDLI.8.6.1279-1281.2001.
10
A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum.
J Pharm Biomed Anal. 1999 Nov;21(3):657-67. doi: 10.1016/s0731-7085(99)00161-2.
Zotero 插件